Genprex, Inc. (GNPX) Spike Almost 250% in Yesterdays Market OpenThe price of Genprex, Inc. (NASDAQ: NASDAQ:GNPX ) stock surge 233% yesterday amidst growing interested in the genetic and pharmaceutical companies.
Further adding to the bullish thesis, Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa gene therapy for the treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics.
While the asset is currently overbought as seen by the RSI at 92, present market metrics shows NASDAQ:GNPX is set to soar 1600% in the near to short term with earnings report slated for November 12, 2025.
The asset is down 17% in premarket trading consolidating before the major spike.
About GNPX
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.
